Blocking soluble guanylate cyclase could be the present and future of NO/cGMP inhibition for vasoplegia treatment. [Carta] (2018)
- Autor:
- Autor USP: EVORA, PAULO ROBERTO BARBOSA - FMRP
- Unidade: FMRP
- DOI: 10.1186/s13054-018-2024-y
- Subjects: RESISTÊNCIA VASCULAR; CHOQUE SÉPTICO
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Critical Care
- ISSN: 1364-8535
- Volume/Número/Paginação/Ano: v. 22, art. 104, 2018
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
EVORA, Paulo Roberto Barbosa. Blocking soluble guanylate cyclase could be the present and future of NO/cGMP inhibition for vasoplegia treatment. [Carta]. Critical Care. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1186/s13054-018-2024-y. Acesso em: 19 abr. 2024. , 2018 -
APA
Evora, P. R. B. (2018). Blocking soluble guanylate cyclase could be the present and future of NO/cGMP inhibition for vasoplegia treatment. [Carta]. Critical Care. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1186/s13054-018-2024-y -
NLM
Evora PRB. Blocking soluble guanylate cyclase could be the present and future of NO/cGMP inhibition for vasoplegia treatment. [Carta] [Internet]. Critical Care. 2018 ; 22[citado 2024 abr. 19 ] Available from: https://doi.org/10.1186/s13054-018-2024-y -
Vancouver
Evora PRB. Blocking soluble guanylate cyclase could be the present and future of NO/cGMP inhibition for vasoplegia treatment. [Carta] [Internet]. Critical Care. 2018 ; 22[citado 2024 abr. 19 ] Available from: https://doi.org/10.1186/s13054-018-2024-y - Budd-chiari syndrome in a 25-year-old woman with behçet's disease: a case report and review of the literature
- Endothelium dysfunction classification [Carta]: keeping the discussion opened
- Effect of the chronic metabollic acidosis on rat thoracic aorta reactivity
- Evolution of the Brazilian Journal of Cardiovascular Surgery [Editorial]
- Vasopressor support sparing strategies [Editorial]: a concept to be incorporated as a paradigm in the treatment of vasodilatory shock
- Why methylene blue is the only option for blocking the cGMP/NO pathway in the treatment of vasoplegic shock? [Editorial]: "reasons that reason itself does not know…"
- Presentation of an experimental method to induce in vitro ("organ chambers") respiratory acidosis and its effects on vascular reactivity
- Possible advances in vasopressors and inotropes support in shock. [Carta]
- Role of nitric oxide production in anaphylaxis and its relevance for the treatment of anaphylactic hypotension with methylene blue
- The 2010 ESC/EACTS guidelines on myocardial revascularization does not present suggestions about disease-free saphenous vein grafts at the time of redo coronary artery bypass grafting. [Carta]
Informações sobre o DOI: 10.1186/s13054-018-2024-y (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
